Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MED 8.94 Congratulations to Medifast Spokesperson Genie Francis of 'General Hospital' Fame Who Won The Daytime Emmy For Best Supporting Actress in a Drama Series
Jun 18, 2007 9:25:00 AM
OWINGS MILLS, Md., June 18 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) announced today that Medifast Spokesperson Genie Francis received her first Daytime Emmy for supporting actress in a drama series.
"Medifast would like to congratulate Genie on this fantastic honor. We are excited for Genie and look forward to working with her to promote the Medifast brand," said Jaime Elwood, VP Corporate Communications.
Genie Francis won the Emmy for her return to the show last year as Laura Spencer, a role she has played since she was 14.
Medifast clients can follow Genie's progress on the Medifast program at the website choosemedifast.com. Genie will be writing an online blog and participating in live chats on the website to interact with Medifast clients.
About Medifast: Medifast (NYSE: MED) www.choosemedifast.com is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) national network of physicians, 3) medically supervised Medifast Weight Control Centers, and 4) the Take Shape For Life direct-selling division, a network of health coaches. Medifast was founded in 1980 and is located in Owings Mills, Maryland.
Media Requests:
Michael Sands
Sands Digital Media, Inc.
310-850-4755
SandsMedia@aol.com
SOURCE Medifast, Inc.
----------------------------------------------
Michael Sands of Sands Digital Media
Inc.
+1-310-850-4755
SandsMedia@aol.com
QVDX 3.09 Quovadx Files Definitive Proxy Statement on Proposed Merger with Quartzite Holdings
Quovadx Stockholders to Receive $3.20 Per Share in Proposed Merger Agreement; Quovadx Board Unanimously Recommends Voting FOR the Transaction
Jun 18, 2007 9:15:00 AM
Copyright Business Wire 2007
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--
Quovadx, Inc. (NASDAQ: QVDX), a global software and vertical solutions company, today announced that it has filed with the Securities and Exchange Commission, and will soon mail to all Quovadx stockholders, its definitive proxy materials urging stockholders to vote "for" the previously announced merger of Quovadx, Inc. and a wholly owned subsidiary of Battery Ventures. Following stockholder approval of the merger agreement, Quovadx shareholders of record as of May 29, 2007 will be entitled to receive $3.20 per share in cash for each share of Quovadx common stock owned, a 25 percent premium when compared to Quovadx's stock price of $2.55 on March 30, 2007 (the last trading day before the proposed merger was announced).
A special meeting of Quovadx stockholders to vote on the proposed merger agreement has been scheduled for July 18, 2007 at 9:00 a.m., local time, at Harlequin Plaza, North Building First Floor Conference Room, 7600 East Orchard Road, Greenwood Village, Colorado 80111. The Quovadx Board of Directors has unanimously approved the agreement and plan of merger and is recommending that Quovadx stockholders vote "for" the approval and adoption of the merger agreement.
Quovadx stockholders of record as of May 29, 2007 will be entitled to vote at the special meeting. Stockholders entitled to vote at the special meeting may also vote by mail, telephone or via the Internet by following instructions included in the proxy statement and printed on the proxy card which accompanies the proxy statement. Quovadx stockholders are reminded that the failure to vote or abstaining from voting has the same effect as a vote against the merger agreement.
If the merger is approved, upon closing of the transaction, Quovadx, Inc. will be wholly owned by Battery Ventures; Quovadx stockholders will receive cash consideration for their shares of Quovadx stock; Quovadx will no longer be a public company and Quovadx common stock will no longer be quoted on The NASDAQ Global Market stock exchange. For the merger to occur, holders of a majority of the outstanding shares of Quovadx common stock entitled to vote must approve and adopt the merger agreement.
Additional Information about the Merger and Where to Find It
This communication is being made in respect of the proposed merger transaction involving Quovadx, Inc. and Battery Ventures. In connection with the transaction, Quovadx, Inc. has filed a definitive proxy statement with the SEC. Quovadx stockholders are urged to read the proxy statement carefully and in its entirety because it contains important information about the proposed transaction. The definitive proxy statement will be mailed to Quovadx stockholders on or about June 18, 2007. In addition, the proxy statement and other documents will be available free of charge from the SEC Internet Web site, http://www.sec.gov. The proxy statement and other pertinent documents also may be obtained for free at Quovadx's Web site, www.investors.quovadx.com or by contacting Rebecca Winning via email at rebecca.winning@quovadx.com, or by phone at 720-554-1346. Quovadx directors, officers, other members of management and employees may be deemed to be participants in the solicitation of proxies in respect to the proposed transactions. Information regarding Quovadx's directors and executive officers is detailed in its annual reports on Forms 10-K, and 10-K/A previously filed with the SEC, and the definitive proxy statement on Form 14A filed with the SEC earlier today.
About Quovadx, Inc.
Quovadx (NASDAQ: QVDX) offers software and services for software system development, extension, and integration to enterprise customers worldwide. Quovadx has two divisions, including the Integration Solutions division (ISD), which offers private and public healthcare and healthcare IT organizations software infrastructure to facilitate system interoperability and leverage existing technology, and, the Rogue Wave Software division, which provides reusable software components and services for enterprise-class application development and high-performance SOA. For more information, please visit www.quovadx.com.
QUOVADX, and QUOVADX logo are registered trademarks or service marks of Quovadx, Inc. in the U.S. and/or select foreign countries. The absence of a trademark from this list does not constitute a waiver of Quovadx, Inc.'s intellectual property rights concerning that trademark. All other company and product names mentioned may be trademarks of the companies with which they are associated
Cautionary Statement
Certain forward-looking statements are included in this release, including statements relating to a proposed transaction between Quovadx, Inc. and Battery Ventures. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Quovadx management's current expectations regarding the proposed transaction, and speak only as of the date of this release. Investors are cautioned that all forward-looking statements in this release involve risks and uncertainties that could cause actual results to differ materially from those referred to in the forward-looking statements. Such risks and uncertainties include, among other things: i) that Quovadx stockholders will not support or approve the transaction in a timely manner, if at all; ii) that the closing of the transaction with Battery Ventures could be materially delayed or more costly and difficult than expected; and/or iii) that the transaction will not be consummated. A full discussion of known risks and uncertainties is included in the Company's Annual Report on Form 10-K, Form 10-K/A and Quarterly Reports on Form 10-Q as filed with the SEC, copies of which are available without charge from the Company. These filings are also available electronically through a link from the Quovadx Investor Relations Web page or from the SEC Web site at www.sec.gov under "Quovadx, Inc." If any of the events described in those filings were to occur, either alone or in combination, it is likely that the Company's ability to reach the results described in the forward-looking statements could be impaired and the Company's stock price could be adversely affected. Quovadx does not undertake any obligation to update or correct any forward-looking statements included in this release to reflect events or circumstances occurring after the date of this release.
Source: Quovadx, Inc.
----------------------------------------------
Quovadx
Inc.
Investor Contact:
Rebecca Winning
720-554-1346
rebecca.winning@quovadx.com
or
Media Contact:
Andrea Lashnits
720-554-1246
andrea.lashnits@quovadx.com
SIRI 2.93 Women Impacting Public Policy Voices Its Support for SIRIUS-XM Merger
WIPP Cites Merger as Beneficial for Women, Small Businesses and Consumers
Jun 18, 2007 9:23:00 AM
WASHINGTON, June 18 /PRNewswire-USNewswire/ -- Women Impacting Public Policy (WIPP) announced its support today of the merger between SIRIUS Satellite Radio (Nasdaq: SIRI) and XM Satellite Radio (Nasdaq: XMSR) in a letter filed with the Federal Communications Commission (FCC).
"WIPP believes the merger of SIRIUS and XM will substantially enhance programming choices by creating a stronger satellite radio company," said WIPP President Barbara Kasoff, in the group's letter to the FCC. "It will also provide a number of important economic benefits for small businesses, clearly benefiting the public interest, and therefore should be approved by the FCC without delay."
SIRIUS and XM provide a breadth of programming choices that appeal to WIPP's membership, who are often underserved by other providers in the broad audio news and entertainment marketplace. For instance, the "one size fits all" model of programming found on terrestrial radio consistently overlooks the particular interests of consumers in favor of more nationalized, homogenous content. This is true of many of WIPP's members, who do not have the same access to programming tailored to their interests as they do on satellite radio.
"Especially relevant to WIPP membership is the prospect of increasing the number of channels offering small business content, particularly issues of special interest to women and minorities in business," added Kasoff.
WIPP is also encouraged by the operational efficiencies and the ensuing pricing benefits consumers will enjoy as a result of the merger. For example, when the merger is approved, consumers will be able to receive a variety of content from both services at a range of prices, including more a la carte offerings and pricing options that cost less than what they would currently pay.
As a national bipartisan public policy organization that advocates for and on behalf of women and minorities in business, WIPP believes the success of this merger will benefit our membership and all consumers nationwide.
About WIPP:
Women Impacting Public Policy is a national bi-partisan group comprising well over half a million members. The non-profit organization is the public policy voice for 47 national Women in Business groups and is The Voice for Women in Business in Our Nation's Capital. WIPP strengthens its members' sphere of influence in the legislative process, creates economic opportunities for members and builds alliances with other small business organizations. Visit http://www.wipp.org.
SOURCE SIRIUS
----------------------------------------------
Anne Sullivan
+1-202-626-8528
for SIRIUS
NABI 5.45 Nabi Biopharmaceuticals Announces Creation of Biologics Business Unit & Provides Strategic Updates
Jun 18, 2007 9:22:00 AM
BOCA RATON, Fla., June 18 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced that it has created the Nabi Biologics strategic business unit (SBU) and expanded the role of Dr. Raafat Fahim, Senior Vice President, Research, Technical and Production Operations, to include the new position of Chief Operating Officer and General Manager of the Biologics SBU. Nabi Biologics is responsible for advancing the company's protein and immunological products and development pipeline, including Nabi- HB(R) [Hepatitis B Immune Globulin (Human)], Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous], HEBIG(TM) [Hepatitis B Immune Globulin (Human) Intravenous], Civacir(R) [Hepatitis C Immune Globulin (Human)], ATG- Fresenius S [Anti-T-Lymphocyte Immune Globulin (Rabbit)], IVIG [Intravenous Immunoglobulin] and Nabi(R) Anti-D [Rho (D) Immune Globulin Intravenous (Human)].
The company also has expanded the role of Jordan Siegel to Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer. In addition to his current role, Mr. Siegel will be responsible for the Corporate Shared Services group, which will streamline and improve all Human Resources, Information Technology and Business Development activities at Nabi and support the company's transition into two independent business units - Nabi Biologics and Nabi Pharmaceuticals.
Nabi also provided today updates regarding the company's ongoing operations, its strategic alternatives process and the Nabi-HB regulatory efforts:
- In connection with the formation of the Nabi Biologics and Corporate
Shared Services groups the company eliminated 32 jobs - approximately 5
percent of its workforce - from which it expects to realize nearly $3
million on an annualized basis.
- The strategic alternatives process is continuing with the support of
Banc of America Securities and Nabi is pursuing discussions for the
sale of the whole or a significant part of the company.
- Nabi has retained the regulatory consulting firm Cato Research Ltd. and
together is working with the U.S. Food and Drug Administration (FDA) to
most expeditiously respond to the FDA's requests and complete its data
submission for Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin
(Human) Intravenous] for the prevention of re-infection with hepatitis
B disease in HBV-positive liver transplant patients. Nabi and Cato
Research have already had several discussions with the FDA to define
the additional data the FDA is seeking from previously-completed
clinical trials. Nabi is currently compiling the additional requested
information.
"Since I became Interim Chief Executive Officer and President of Nabi in February of this year, we have focused and energized the approach of our strategic alternatives process and have leveraged the expertise and success of Cato Research to work more effectively with the FDA to secure expanded regulatory approvals for Nabi-HB," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi Biopharmaceuticals. "We are achieving the strategic corporate goals that will help us realize the value of our pipeline - the creation of Nabi Biologics and, soon, Nabi Pharmaceuticals."
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has one product on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram- positive bacterial infections and nicotine addiction. The company has just announced the formation of the first of two strategic business units: Nabi Biologics. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi-HB. The second business unit, Nabi Pharmaceuticals, is expected to be formed later this year and will have responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs, as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate). For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.
Forward-Looking Statements
Statements in this release that are not strictly historical are forward- looking statements and include statements about reorganization of our current business into two new business units, our strategic alternatives process and clinical trials and studies. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward- looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: realize anticipated cost savings related to job elimination due to greater than anticipated severance-related costs or other factors; successfully partner with third parties to fund, develop, manufacture and/or distribute our existing and pipeline products, including NicVAX and our Gram- positive infections products; obtain successful clinical trial results; our ability to successfully complete our strategic alternatives process; generate sufficient cash flow from sales of products or from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to commercialize current products and bring to market products in development; depend upon third parties to manufacture or fill our products; obtain regulatory approval for our products in the U.S. or other markets, including approval of Nabi-HB Intravenous; realize sales from Nabi-HB due to patient treatment protocols, the number of liver transplants performed in HBV-positive patients and competitive products; achieve market acceptance of our products; expand our sales and marketing capabilities or enter into and maintain arrangements with third parties to market and sell our products; effectively and/or profitability use, or utilize the full capacity of, our vaccine manufacturing facility; manufacture NicVAX or other products in our own vaccine manufacturing facility; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report for the quarter ended March 31, 2007 on Form 10-Q with the Securities and Exchange Commission.
SOURCE Nabi Biopharmaceuticals
----------------------------------------------
Investor Relations for Nabi Biopharmaceuticals
+1-561-989-5800
HDY 3.00 Hyperdynamics Adds Patton Boggs LLP to its Team; Former U.S. Congressman Chris Bell Takes Lead Role for Managing US Government Relationships
Jun 18, 2007 9:20:00 AM
Copyright Business Wire 2007
HOUSTON--(BUSINESS WIRE)--
Hyperdynamics Corporation (AMEX:HDY) announced today that it has engaged the firm of Patton Boggs, LLP as legal counsel for public policy issues in Washington, DC as they are related to the Company's international mission for oil and gas exploration off the coast of West Africa. Former U.S. Congressman Chris Bell, now Of Counsel with Patton Boggs, has become lead counsel for Hyperdynamics and will have the extensive resources of the firm to draw on for support.
When asked to comment, Chris Bell said, "This is a very interesting and exciting project for us to be a part of. Last week we were able talk candidly with the Prime Minister of Guinea, understanding his desire to encourage Hyperdynamics to increase investment in Guinea. We look forward to helping our client develop the relationships with key US Government officials that can continue to strengthen their international relations in countries in which they are operating in now and others in the future. Additionally, our client base has strong financial interests in oil and gas and we believe there could be significant interest to join Hyperdynamics' offshore Guinea exploration efforts."
About Hyperdynamics
Hyperdynamics Corporation provides energy for the future by exploring and producing sources of energy worldwide. The company's internationally active oil and gas subsidiary, SCS Corporation, owns rights to explore and exploit 31,000 square miles offshore the Republic of Guinea, West Africa. HYD Resources Corporation focuses on domestic production in proven areas. To find out more about - Hyperdynamics Corporation, visit our Website at http://www.hyperdynamics.com.
About Patton Boggs LLP
For more than 40 years, Patton Boggs has maintained a reputation for cutting-edge advocacy by working closely with Congress and regulatory agencies in Washington, litigating in courts across the country, and negotiating business transactions around the world. The firm includes individuals with extensive backgrounds in government service with strong ties to both major political parties, as well as top-flight litigators and individuals with a keen understanding of business and finance.
About Chris Bell
Former U.S. Congressman Chris Bell combines his knowledge of political strategy and public policy with his large network of public and private sector contacts throughout Texas and Washington, D.C. to assist clients with a variety of government relations matters.
While serving in the U.S. House of Representatives (District 25, Texas), Mr. Bell was Senior Whip, Chair and Founder of the Congressional Port Security Caucus, and a member of the Committees on Financial Services, International Relations, Science, and Government Reform. While in congress, he traveled extensively to foreign countries such as Iraq, India, and Israel with various delegations. In 2006, he was the Democratic nominee for Governor of Texas. Before serving in the House, he served five years as a member of the Houston City Council. Mr. Bell joined Patton Boggs earlier this year.
Forward Looking Statements
Statements in this news release are "forward looking" as defined by the U.S. Securities and Exchange Commission and are based on expectations, beliefs or projections that are subject to numerous risks and uncertainties. Investors are cautioned that these statements are not guarantees of future performance, and actual results could differ materially. Please refer to "Risk Factors" in the company's Form 10-K filed with the SEC.
# # #
HDY-IR
Source: Hyperdynamics Corporation
----------------------------------------------
For Hyperdynamics Corporation
Investor Awareness
Inc.
Tony Schor or Lindsay Kenoe
847-945-2222
www.investorawareness.com
or
Roher Public Relations
Phillip Bergman
914-238-2200
ext 302
Vice President
lol!~ PLEASE ADD "SMART MONEY BUYING AT THESE CHEAP LEVELS" lol
AURC Aurus Changes Transfer Agent
Jun 15, 2007 2:34:00 PM
NEW YORK, NY -- (MARKETWIRE) -- 06/15/07 -- Aurus Corp. (PINKSHEETS: AURC) advises its shareholders that it has changed its transfer agent and the latter is proceeding to fulfill the regulatory requirements to effect the distribution of the dividend.
Martin Grancharoff has resigned for health reasons as the Vice President and the Company's North American representative shall be chosen.
Aurus Corporation is a publicly traded mining holding company with several precious metal properties with over 5 million ounces in gold reserves, trading under the ticker symbol AURC on the US Pinksheets market. Aurus seeks to continue to acquire proven gold and other precious metal reserves in Russia and other emerging counties and operates its mines through joint ventures and/or partnerships.
Contact:
Jeremy Krause
Managing Director
Business Development Consultants, LLC
1-858-384-0294
i am heading out....both TDA accts down so i may as well go outside! :) happy friday
New Wave Media Inc and Playstar update shareholders on dividend
Jun 15, 2007 2:14:00 PM
TORONTO, June 15 /PRNewswire-FirstCall/ - New Wave Media Inc (OTC: NWWV.PK) and Playstar Corporation (OTC: PLYCF.PK) would like to update shareholders of both companies on the dividend to its shareholders and a new corporate development.
The dividend record date will be moved to the close on June 22nd 2007 and still be payable on or about July 12th 2007. A further release with the Ex dividend date will be forthcoming shortly.
New Wave Media has been presented along with Wagerphone a major licensing opportunity that our legal team and 2 advisors are currently analyzing which may affect our dividend payout but NOT our merger between Playstar and New Wave Media as the opportunity involves all products.
New Wave Media currently has 137,000,000 restricted and 117,000,000 free trading shares for a total of 254,000,000 and the transfer agent is transfer Online of Portland Oregon.
This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in New Wave Mobile reports that will be on file with the US Securities and Exchange Commission.
www.wagerphone.com
SOURCE New Wave Media Inc.
----------------------------------------------
www.wagerphone.com
CWNN CandleWealth International, Inc. Announces New Trading Symbol, Name Change, and Reverse Stock Split
Jun 15, 2007 2:13:00 PM
Copyright Business Wire 2007
CHATSWORTH, Calif.--(BUSINESS WIRE)--
CandleWealth International, Inc. (OTC Pink Sheets:CWNN), announced that effective today its name has changed from CandleWealth International, Inc. to Promethean Corporation and effective at the open of business June 18, 2007, its trading symbol will change from CWNN to PRMN.
The company also announced today that it has completed its one (1) for five (5) reverse stock split of its common stock, and that all of the company's operations have been successfully transferred to a newly created wholly owned subsidiary whereby the company, Promethean Corporation, is now the publicly traded holding company for the new subsidiary, which is named CandleWealth International, Inc.
The company's board of directors believes these changes will create a more rational capital structure for the Company, which in turn, will enable the company to raise additional capital and facilitate the Company's strategy to grow and diversify its operations beyond the current CandleWealth International, Inc. operations.
About CandleWealth International, Inc.
CandleWealth is a direct seller of natural, soy-based candle wax, candle making supplies and other related products. Its home-based independent distributors make and sell these candles as well as build teams of other candle makers who do the same. Soy wax is a cleaner alternative to petroleum-based paraffin wax, burning cooler and longer, without the residues inherent in paraffin wax smoke. CandleWealth's success will be driven by the zeal and excitement of its distributors in spreading the benefits of natural wax and CandleWealth's other innovative products.
Safe Harbor Statement
Some of the information presented in this letter constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Although the company believes it has a reasonable basis for these forward-looking statements, the company cannot guarantee their accuracy and actual results may differ materially from those the company anticipated due to a number of known and unknown uncertainties, of which the company is not aware. Factors which could cause actual results to differ from expectations include, among others, the company's historic lack of profitability, end user customer acceptance and actual demand, which may differ significantly from expectations, the need for the company to manage its growth, the need to raise funds for operations and other risks within the regulation of the industry.
For more information, call Dave Koerner at CandleWealth International at 888-881-9373 or visit their website at www.candlewealth.com.
Source: CandleWealth International, Inc.
----------------------------------------------
CandleWealth International
Dave Koerner
888-881-9373
www.candlewealth.com.
NABI 4.92 Chapman Capital Supports Sale of Nabi Biologics Division of Nabi Biopharmaceuticals
Investment Advisor Seeks NicVAX(R) Strategic Partnering
Jun 15, 2007 1:57:00 PM
LOS ANGELES, June 15 /PRNewswire/ -- Chapman Capital L.L.C., investment advisor to two investment funds that together own 6.6% of the common shares of Nabi Biopharmaceuticals (Nasdaq: NABI; "Nabi" or "the Company"), today announced its support for the maximization of Nabi shareholder value via a three-step transaction. This mandate, conveyed to Nabi's Board of Directors by nearly 40% of Nabi's ownership base, has been defined as follows: 1) FDA approval of Nabi's BLA for Nabi-HB(R) Intravenous; 2) the distribution of the proceeds from the sale of Nabi Biologics; and 3) partnering/licensing of Nabi's vaccine pipeline led by smoking cessation drug, NicVAX(R) (Nicotine Conjugate Vaccine).
Robert L. Chapman, Jr., Managing Member of Chapman Capital, commented, "Unlike many of our activist targets, Nabi is not yet worthy of our disdain or disgust. The Company has taken the necessary steps to prepare for its restructuring and recapitalization. Nabi has bifurcated itself into two strategic business units to facilitate the successful completion of its strategic alternatives process being overseen by Banc of America Securities, and has committed to reduce further its cost structure and cash burn. These developments give Chapman Capital confidence that Nabi CEO Dr. Leslie Hudson is a man of his word, with that word being 'execution' (walk) and not the formerly insuperable one of 'vision' (talk)."
Chapman Capital today filed a Schedule 13D with the Securities and Exchange Commission detailing the circumstances and background underlying its views. Such filing is available at http://www.sec.gov.
Chapman Capital L.L.C. is a Los Angeles, CA based investment advisor focusing on takeover and turnaround investing. The firm is the registered investment advisor to Chap-Cap Partners II Master Fund, Ltd. and Chap-Cap Activist Partners Master Fund, Ltd., the combined owners of approximately 6.6% of Nabi Pharmaceuticals' common shares. Over the past eleven years, Chapman Capital has agitated successfully for the restructuring or sale of over twenty five publicly-traded companies, including recently closed transactions involving Entertainment Distribution Company, Inc./Glenayre Messaging, Carreker Corporation and Sunterra Corporation, and pending transactions involving Embarcadero Technologies, Inc., Agile Software Corporation and Howie Lutnick's eSpeed, Inc. Mr. Chapman previously was employed by Goldman Sachs & Co., Scudder Stephens, & Clark, and NatWest Bank USA. Related news releases, as well as additional information on Chapman Capital, may be found at http://www.chapmancapital.com.
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has one product on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. The company recently announced that it intends to form two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics will have responsibility for the company's protein and immunological products and development pipeline, including Nabi-HB(R). Nabi Pharmaceuticals will have responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R)-Pentavalent (Staphylococcal Polysaccharide Conjugate and Toxoid Vaccine) development programs, as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate). Related news releases, as well as additional information on Nabi, may be found at http://www.nabi.com.
SOURCE Chapman Capital L.L.C.
----------------------------------------------
R. Jordan Frenkel of Chapman Capital L.L.C.
+1-310-662-1900
ext. 209
13:32 6/18/2007 GEYC 1-5.1 R/S ** Green Energy Holding Corp. Common Stock (NV) GEYO Green Energy Holding Corp New Common Stock (NV)
13:32 6/18/2007 EDRI 1-20 R/S ** EDOLLARS INC. Common Stock FRXI Forex Inc Common Stock
6/18/2007 CWNN 1-5 R/S ** Candlewealth International, Inc. Common Stock PRMN Promethean Corporation Common Stock
ATSI 1.63 ATS Medical Participating in Society of Heart Valve Disease Meeting
Jun 15, 2007 1:37:00 PM
MINNEAPOLIS, June 15 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI) is looking forward to its participation in the 4th Biennial Meeting of the Society of Heart Valve Disease. The event runs June 15-18, 2007 and will attract cardiovascular surgeons from around the world to its venue at the Hotel Pennsylvania in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
Noteworthy for ATS Medical are several presentations focusing on products in their expanding portfolio of cardiac surgery offerings.
-- "Effects of Aortic Prosthetic Valve Design on Coronary Flow Velocity
Profiles" from the John Radcliffe Hospital in Oxford, United Kingdom
reports on improvements in coronary flow seen with the ATS 3f Aortic
Bioprosthesis.
-- "Five Years Clinical Experience with the 3f Stentless Aortic
Bioprosthesis" from Johann Wolfgang Goethe University in Frankfurt,
Germany documents excellent midterm clinical performance, improved
implantability and excellent restoration of coronary blood flow.
-- "Hemodynamic and Clinical Outcome in Bovine and Equine Stentless
Pericardial Aortic Valve Bioprostheses: Three Years Follow-up" from
the University of Berlin Charite demonstrated hemodynamic benefits for
the ATS 3f Aortic Bioprosthesis.
-- "Ten-year Results of the ATS Open Pivot Bileaflet Heart Valve" from the
National Cardiovascular Center in Osaka, Japan documents the low long
term complication rates associated with ATS mechanical valve
implantation.
-- "Cryomaze Using Argon-based Cryoablation Is Highly Effective Therapy
During Complex Valve Procedures" describes the favorable experience of
Harold G. Roberts, MD and colleagues from South Florida Cardiovascular
Surgical Associates in Ft. Lauderdale, Florida, using CryoCath
technology for the surgical ablation of cardiac arrhythmias.
Michael D. Dale, Chairman, President and CEO of ATS Medical noted, "Surgeons rely heavily on the reported experience of their colleagues in making product decisions. A critical component in our success going forward will lie in our ability to foster an environment and product mix that attracts the interest of physicians and scientists who are respected researchers. The activity surrounding products in our portfolio at this year's Society of Heart Valve Disease Meeting is ample evidence that we are making strides towards that objective."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, has been headquartered in Minneapolis, Minnesota. More than 135,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3F(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, SurgiFrost(R) and FrostByte(R) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3F Therapeutics, regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.
SOURCE ATS Medical, Inc.
----------------------------------------------
Michael Dale
President-CEO
+1-763-553-7736
or Michael Kramer
Senior Director of Finance
+1-763-557-2222
both of ATS Medical
Inc.; or Investors
Jennifer Beugelmans
+1-646-201-5447
or Doug Sherk
+1-415-896-6820
or Media
Jennifer Saunders
+1-646-201-5431
all for ATS Medical
Inc.
SRGG .49 Surge Global Energy Announces Sale of Red Earth Assets for CDN$20 Million
Jun 15, 2007 1:32:00 PM
2007 PrimeNewswire, Inc.
SAN DIEGO, June 15, 2007 (PRIME NEWSWIRE) -- Surge Global Energy, Inc. (OTCBB:SRGG) ("Surge" or the "Company") is pleased to announce that it and its indirect wholly-owned subsidiary, Peace Oil Corp., has entered into a binding letter agreement with Peace Oil's current joint venture partner, North Peace Energy Corp., to sell all of Peace Oil's working interest (30%) in certain oil sands leases in the Red Earth Area of north central Alberta, Canada. Total consideration for the sale is CDN$20 million, consisting of CDN$15 million in cash and CDN$5 million in common shares of North Peace (2,272,727 common shares at a deemed price of CDN$2.20 per share). The common shares issued will be subject to a contractual one-year hold period. The acquisition is expected to close on or about June 28, 2007 and no later than September 1, 2007.
The CDN$20 million in North Peace consideration compares to Surge's CDN$16.620 million acquisition cost of Peace Oil in March 2007 and Surge's March 31, 2007 Peace Oil book value of US$14.4 million. Upon completion of the asset sale, North Peace will control 100 percent of the parties' leases in the Red Earth Area. North Peace has indicated via recent press release that it is confident in the commercial potential of the leases in the Red Earth Area and confirmed that plans for a Cyclic Steam Stimulation pilot project are advancing as scheduled, with the first steam cycle expected in late 2008 or early 2009.
About Surge Global Energy, Inc.
Surge Global Energy, Inc. is an early stage oil and gas exploration and production company. Surge seeks to invest and acquire properties in the oil sands regions of Canada. Surge also has an interest in an exploration stage oil and gas project in Argentina and is looking to identify, acquire and develop working interests in other underdeveloped oil and gas projects in socially and politically stable regions. For more information please visit our Investor Center at: www.surgeglobalenergy.com.
The Surge Global Energy, Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2471
Forward-Looking Statements
Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.
Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.
Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the sections entitled "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in our most recent Annual Report on Form 10-KSB, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Such factors include, but are not limited to, risks and uncertainties relating to the possibility that Surge will not discover bitumen, oil or gas in the quantities the Company currently anticipates. To fund the probable and proven reserve development cost effort, we anticipate raising a significant amount of capital which will result in substantial future dilution to existing shareholders. Other factors besides those listed there could also adversely affect our results.
CONTACT: Surge Global Energy, Inc.
David Perez, Chief Executive Officer and Chairman
of the Board
858.704.5018 (Direct)
858.704.5010 (Main)
Fax: 858.704.5011
david@surgeglobalenergy.com
the heck u say...in pennyland???!! NOOOOOOOOO, say it ain't so.
AMAR .64 Amarillo Biosciences Announces Upcoming Clinical Trial of Oral Interferon Therapy for Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease
Jun 15, 2007 1:29:00 PM
AMARILLO, TX -- (MARKETWIRE) -- 06/15/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Lorenz Lutherer, MD, PhD, Texas Tech University Health Services Center (TTUHSC) has been granted funding from the School of Medicine of TTUHSC to conduct a study on oral interferon therapy for chronic cough in patients with chronic obstructive pulmonary disease (COPD). The funding from the university will be available on September 1, 2007. Accordingly, ABI will immediately commence preparation of the Investigational New Drug (IND) application to the FDA. Clinical supplies of interferon lozenges and placebo will be packaged for the double-blinded, randomized clinical study.
Treatment with oral interferon or a placebo preparation will be three times per day for 4 weeks with 4 weeks of post-treatment observation to test the duration of any effect observed. The primary endpoint will be reduction in cough frequency/severity. Digital recordings will assess cough frequency and visual analog scale (VAS) will assess cough severity. Possible effects on the quality of life with suppression of the cough will also be assessed.
Dr. Lutherer noted that, "In our previous study in patients with idiopathic pulmonary fibrosis (IPF), we found preliminary evidence that treatment with oral interferon suppressed the chronic cough associated with that disease, so we are hopeful that it will have a similar effect in patients with COPD."
COPD is caused by damage to the small airways, usually due to smoking. COPD is reported to affect 10% of humans over the age of 40. By the year 2030, the World Health Organization (WHO) predicts that COPD will become the fourth most common cause of death, behind only heart disease, cerebrovascular disease and HIV/AIDS. COPD is the only common cause of death in the United States that has increased over the last 40 years in sharp contrast to the reduction in cardiovascular and infectious diseases.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Bioscience's shares and has provided over $12.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.
Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: Email Contact
Tel: 800-477-7570; 212-344-6464
Fax: 212-618-1276
Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: Email Contact
Tel: 806-376-1741 x 13
Fax: 806-376-9301
ARCI 4.50 Appliance Recycling Centers of America Awarded Multi-Year Appliance Recycling Contract Totaling Up To $40 Million (U.S.) By Ontario Power Authority
Jun 15, 2007 1:28:00 PM
Copyright Business Wire 2007
MINNEAPOLIS--(BUSINESS WIRE)--
Appliance Recycling Centers of America, Inc. (Nasdaq:ARCI) today announced that its Canadian subsidiary, ARCA Canada Inc., has been awarded a multi-year contract of up to $40 million ($44 million Canadian) to recycle older, inefficient but working refrigerators, freezers and room air conditioners by the Ontario Power Authority (OPA).
Aimed at reducing energy consumption throughout the province of Ontario by taking inefficient appliances out of service, the program is scheduled to commence June 25 and run through the end of 2010. If this year's recycling targets are met, ARCA would realize revenues of approximately $3 to $4 million over the balance of 2007.
Under terms of the OPA program, ARCA will collect eligible appliances from homes and then recycle them in an environmentally responsible manner, adhering to all governmental laws and standards. To handle projected recycling volumes, ARCA will expand its appliance recycling center in Ontario previously used for handling a pilot project with the OPA. Additional local jobs will be created as a result of this investment.
Edward R. (Jack) Cameron, ARCA's president and chief executive officer, commented: "We sincerely thank the OPA for the confidence it is showing in ARCA and our advanced recycling technologies. Given our pioneering efforts in large-scale appliance recycling and proven track record that extends back to the late 1980s, we believe ARCA will meet the needs and expectations of our OPA partner."
He continued: "Appliance recycling programs like the OPA's are a proven means for achieving significant energy savings, which can reduce the need for additional electrical generation capacity. Over the past year, we have seen growing interest in such programs among electric utilities and government agencies in view of persistently high energy costs, and both the OPA and previously announced Los Angeles Department of Water and Power programs appear to bear out this contention. As the nation's leading provider of appliance recycling services, we believe ARCA is well-positioned to continue benefiting from the growing need for energy conservation."
About ARCA
ARCA is one of the nation's largest recyclers of major household appliances for the energy conservation programs of electric utilities and government agencies. Through its ApplianceSmart operation, ARCA also is one of the nation's leading retailers of special-buy household appliances, primarily those manufactured by Maytag, GE, Frigidaire and Whirlpool. These special-buy appliances, which include close-outs, factory overruns and scratch-and-dent units, typically are not integrated into the manufacturer's normal distribution channel. ApplianceSmart sells these virtually new appliances at a discount to full retail, offers a 100% money-back guarantee and provides warranties on parts and labor. As of June 2007, ApplianceSmart was operating 15 factory outlets: five in the Minneapolis/St. Paul market; three in the Columbus, Ohio, market; four in the Atlanta market; two in San Antonio, Texas and one in Los Angeles.
Statements about ARCA's outlook are forward-looking and involve risks and uncertainties, including but not limited to: the strength of recycling programs, the growth of appliance retail sales, the speed at which individual retail stores reach profitability, and other factors discussed in the Company's filings with the Securities and Exchange Commission.
Source: Appliance Recycling Centers of America, Inc.
----------------------------------------------
Appliance Recycling Centers of America
Inc.
Edward R. (Jack) Cameron
CEO
952-930-9000
or
Equity Market Partners
Richard G. Cinquina
904-415-1415
i delivered the news..dunno anything here but wish those in best of luck.
happy birthday then! LOL GL folks :)
PANAMERSA Corporation Announces Look at New Exchange
Jun 15, 2007 1:00:00 PM
DALLAS, TX and PANAMA CITY -- (MARKETWIRE) -- 06/15/07 -- PANAMERSA Corporation (PINKSHEETS: PNMS) and DESIMPLEX today change the course of history with completion of the PDR Exchange (Panama), Inc. and the trading site www.pdrexchange.com. Through Fundacion Pan America, the site establishes the means necessary for the exchange to be fundamentally operational and trading globally 24 hours a day - seven days a week -- a new innovative process for investors. Projected gross revenues from this venture are estimated at $271 million over the next five years.
"This site is fully functional and provides the platform needed for all beneficiaries of Fundacion Pan America to trade amongst themselves while also establishing a safe haven for their investments and holdings," said Mike Terrell, CEO of PANAMERSA Corporation. Mr. Terrell also stated, "This beginning addresses the sense of belonging paramount to our success incorporating a vision conceived over thirty years ago."
While American Depository Receipts (ADR) are commonplace and allow Americans to participate in offshore entities, Pan American Depository Receipts (PDR) provide opportunities for people unilaterally to participate in the growth and economic integration of Latin America into the western hemisphere and the world. Membership in Fundacion Pan America is required prior to participation; however, once an account is established through the Fundacion, it can be used as an asset depository. As with any depository Fundacion, bank or IRA, a member will be issued receipts (PDRs) for assets held within Fundacion Pan America. Mr. Terrell also emphasizes that membership is for individuals, legal entities, or governments in good standing.
PDRs are the result of a diverse group of visionaries whose goal is to affect a more intelligent, effective means of conducting business; however, more importantly it provides a unique opportunity to unite all of Pan America.
More information can be found on PDR Exchange (Panama), Inc.'s home page, www.pdrexchange.com. The opening of the exchange is expected Tuesday, June 19, 2007. PANAMERSA Corporation welcomes the viewing of screen shots of the exchange by visiting the above referenced website address.
PANAMERSA Corporation (PINKSHEETS: PNMS) is a holding company for a group of business enterprises, which promotes the commercial integration of Latin America into the economic development of the Western Hemisphere. PANAMERSA Corporation is engaged in global e-commerce and e-biz solutions offering interactive e-commerce and e-biz programs in addition to a range of goods and services online including: prepaid Debit cards; e-commerce merchant accounts; life insurance policies, gold transactions; telephony services, text messaging, VoIP, Micro Forests properties, real estate investment participations, fixed and variable income real estate properties in Costa Rica and Panama, offshore financial services, asset management and protection; travel services, leisure, business, health, relocation services, and digital marketing services.
Forward-looking statements are not historical facts as "forward-looking statements" defined in the Private Securities Litigation Reform of 1995. Forward-looking statements are not guarantees of future performance. Our forward-looking statements are the result of profound analysis on trends in our globalizing economies that we anticipate in our industry. It is our good faith vision and estimate of the effect on the globalization, integration and electronic business trends will have on our company. Our statements are also subject to risks and uncertainties beyond our reasonable control that could cause the results of operations to differ materially from those reflected in our forward-looking statements.
Contact:
Investor Relations
214-774-4870
Market News First
Angela Junell
214-461-3411
PNMS .0017 PANAMERSA Corporation Announces Look at New Exchange
Jun 15, 2007 1:00:00 PM
DALLAS, TX and PANAMA CITY -- (MARKETWIRE) -- 06/15/07 -- PANAMERSA Corporation (PINKSHEETS: PNMS) and DESIMPLEX today change the course of history with completion of the PDR Exchange (Panama), Inc. and the trading site www.pdrexchange.com. Through Fundacion Pan America, the site establishes the means necessary for the exchange to be fundamentally operational and trading globally 24 hours a day - seven days a week -- a new innovative process for investors. Projected gross revenues from this venture are estimated at $271 million over the next five years.
"This site is fully functional and provides the platform needed for all beneficiaries of Fundacion Pan America to trade amongst themselves while also establishing a safe haven for their investments and holdings," said Mike Terrell, CEO of PANAMERSA Corporation. Mr. Terrell also stated, "This beginning addresses the sense of belonging paramount to our success incorporating a vision conceived over thirty years ago."
While American Depository Receipts (ADR) are commonplace and allow Americans to participate in offshore entities, Pan American Depository Receipts (PDR) provide opportunities for people unilaterally to participate in the growth and economic integration of Latin America into the western hemisphere and the world. Membership in Fundacion Pan America is required prior to participation; however, once an account is established through the Fundacion, it can be used as an asset depository. As with any depository Fundacion, bank or IRA, a member will be issued receipts (PDRs) for assets held within Fundacion Pan America. Mr. Terrell also emphasizes that membership is for individuals, legal entities, or governments in good standing.
PDRs are the result of a diverse group of visionaries whose goal is to affect a more intelligent, effective means of conducting business; however, more importantly it provides a unique opportunity to unite all of Pan America.
More information can be found on PDR Exchange (Panama), Inc.'s home page, www.pdrexchange.com. The opening of the exchange is expected Tuesday, June 19, 2007. PANAMERSA Corporation welcomes the viewing of screen shots of the exchange by visiting the above referenced website address.
PANAMERSA Corporation (PINKSHEETS: PNMS) is a holding company for a group of business enterprises, which promotes the commercial integration of Latin America into the economic development of the Western Hemisphere. PANAMERSA Corporation is engaged in global e-commerce and e-biz solutions offering interactive e-commerce and e-biz programs in addition to a range of goods and services online including: prepaid Debit cards; e-commerce merchant accounts; life insurance policies, gold transactions; telephony services, text messaging, VoIP, Micro Forests properties, real estate investment participations, fixed and variable income real estate properties in Costa Rica and Panama, offshore financial services, asset management and protection; travel services, leisure, business, health, relocation services, and digital marketing services.
Forward-looking statements are not historical facts as "forward-looking statements" defined in the Private Securities Litigation Reform of 1995. Forward-looking statements are not guarantees of future performance. Our forward-looking statements are the result of profound analysis on trends in our globalizing economies that we anticipate in our industry. It is our good faith vision and estimate of the effect on the globalization, integration and electronic business trends will have on our company. Our statements are also subject to risks and uncertainties beyond our reasonable control that could cause the results of operations to differ materially from those reflected in our forward-looking statements.
Contact:
Investor Relations
214-774-4870
Market News First
Angela Junell
214-461-3411
SGN .88 Signalife to Present at the 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Jun 15, 2007 12:54:00 PM
GREENVILLE, S.C., June 15 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced that its manuscript entitled "Evaluation of Novel ECG Signal Processing on Quantification of Transient Ischemia and Baseline Wander Suppression" was accepted as contributed paper by the IEEE Engineering in Medicine and Biology Society (EMBS). This paper will be presented at the 29th Annual International Conference (EMBC 2007) to be held in Lyon, France from August 23-26, 2007. The manuscript was authored by the Signalife R&D team and Mitchell W. Krucoff, MD, Professor of Medicine at Duke University Medical Center, Durham, North Carolina.
The Institute of Electrical and Electronics Engineers (IEEE) is the world's leading professional association for the advancement of technology. EMBS, an IEEE society, is the largest international society of Biomedical Engineers with approximately 8,000 members throughout the world. It focuses on the application of concepts and methods of the physical and engineering sciences in biology and medicine. The EMBC 2007 will offer an opportunity to gather researchers, educators, and developers from academic fields and industries worldwide to share their research results and exchange ideas from all areas of biomedical engineering. The conference technical program will spotlight industrial research and leadership in the areas of biomedical engineering, biological sciences, medical physics, healthcare technologies and informatics, and pharmaceuticals. The conference will be held in conjunction with the biennial Conference of the French Society of Biological and Medical Engineering (SFGBM).
Budimir S. Drakulic, PhD, Signalife CTO commented: "This conference provides a significant opportunity for Signalife to present results of Fidelity 100 tests to the world-wide audience of biomedical engineers. Our manuscript reports clinical data obtained during DIVA study together with the data obtained during objective evaluation of Fidelity 100. We have evaluated Fidelity 100 against modern electrocardiographs from leading industry manufacturers using a simulator and ECG waveforms obtained from the MIT-BIH ST Change Database and the European ST-T Database. We believe that this paper and presentation, along with other upcoming papers to be submitted to the Journal of Cardiology, will confirm significance of Fidelity 100 and its technology to the ECG community."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
----------------------------------------------
Kevin Kading of Signalife
Inc.
+1-212-918-4606
hey glassy(since u have the day off)....would u give me your thoughts here? NNSR chart
Eternal Image Expands Exclusive Distribution Agreement with P&J Cooper Supply Company
Agreement Includes Nearly All of New York State, Pennsylvania and Maryland
Jun 15, 2007 12:26:00 PM
Copyright Business Wire 2007
FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--
Eternal Image, Inc. (OTC:ETIM.PK), a public company engaged in the design, manufacturing and marketing of licensed image caskets and urns, today announced that it has expanded its distribution agreement with P&J Cooper Supply Company based in Barrington, New Jersey.
P&J Cooper Supply Company currently distributes the complete Eternal Image line of licensed image caskets and urns in the metropolitan New York area (including the 5-boroughs of New York City), Long Island, New Jersey, metro-Philadelphia, Delaware and the Eastern Shore of Maryland. The expanded agreement now includes nearly all of New York State and Pennsylvania (except for the counties bordering eastern Ohio which are covered by another resource) and all of Maryland.
"P&J Cooper Supply has been an early and ongoing supporter of Eternal Image and we are very pleased that they felt it important to expand their distribution areas," said Clint Mytych, president, Eternal Image. "Their support of the product line has meant sell-out success in their regions for nearly all of our currently available products and we look forward to growing our business with them in the coming years.
P&J Cooper Supply has been in business since 1979. The firm is also a distributor for Wilbert Burial Vaults. P&J principal partner Paul Cooper is a licensed funeral director who has worked in the industry since 1971. He serves as a member of the Board of Directors of Wilbert, Inc. His daughter, Beth Cooper serves as vice president of the company.
"Eternal Image products are changing the way funeral homes are coordinating services," said Beth Cooper. "Having the ability to provide products that reflect the interests and passions of a loved one makes a funeral so much more personal, and our sales of Eternal Image products are bearing out the belief that there really is a market for these items."
Eternal Image manufactures and markets licensed image funerary products featuring The Vatican Library Collection(TM), Major League Baseball(R), Precious Moments(TM) and American Kennel Club(TM) and Cat Fanciers' Association(TM) (for pet products.)
For more information about EI, visit the website at www.eternalimage.net or call 1-888-6-CASKET.
SAFE HARBOR STATEMENT
Statements in this news release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may", "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or similar terms or the negative of these terms.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.
Source: Eternal Image, Inc.
----------------------------------------------
Investor Relations Contact:
Cambridge Investor Relations
Tony Fazio
781-214-9038
cambridgeir@comcast.net
or
Media Relations:
a.s.a.p.r.
Robbie Tarpley Raffish
410-883-2000
ETIM .0042 Eternal Image Expands Exclusive Distribution Agreement with P&J Cooper Supply Company
Agreement Includes Nearly All of New York State, Pennsylvania and Maryland
Jun 15, 2007 12:26:00 PM
Copyright Business Wire 2007
FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--
Eternal Image, Inc. (OTC:ETIM.PK), a public company engaged in the design, manufacturing and marketing of licensed image caskets and urns, today announced that it has expanded its distribution agreement with P&J Cooper Supply Company based in Barrington, New Jersey.
P&J Cooper Supply Company currently distributes the complete Eternal Image line of licensed image caskets and urns in the metropolitan New York area (including the 5-boroughs of New York City), Long Island, New Jersey, metro-Philadelphia, Delaware and the Eastern Shore of Maryland. The expanded agreement now includes nearly all of New York State and Pennsylvania (except for the counties bordering eastern Ohio which are covered by another resource) and all of Maryland.
"P&J Cooper Supply has been an early and ongoing supporter of Eternal Image and we are very pleased that they felt it important to expand their distribution areas," said Clint Mytych, president, Eternal Image. "Their support of the product line has meant sell-out success in their regions for nearly all of our currently available products and we look forward to growing our business with them in the coming years.
P&J Cooper Supply has been in business since 1979. The firm is also a distributor for Wilbert Burial Vaults. P&J principal partner Paul Cooper is a licensed funeral director who has worked in the industry since 1971. He serves as a member of the Board of Directors of Wilbert, Inc. His daughter, Beth Cooper serves as vice president of the company.
"Eternal Image products are changing the way funeral homes are coordinating services," said Beth Cooper. "Having the ability to provide products that reflect the interests and passions of a loved one makes a funeral so much more personal, and our sales of Eternal Image products are bearing out the belief that there really is a market for these items."
Eternal Image manufactures and markets licensed image funerary products featuring The Vatican Library Collection(TM), Major League Baseball(R), Precious Moments(TM) and American Kennel Club(TM) and Cat Fanciers' Association(TM) (for pet products.)
For more information about EI, visit the website at www.eternalimage.net or call 1-888-6-CASKET.
SAFE HARBOR STATEMENT
Statements in this news release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may", "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or similar terms or the negative of these terms.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.
Source: Eternal Image, Inc.
----------------------------------------------
Investor Relations Contact:
Cambridge Investor Relations
Tony Fazio
781-214-9038
cambridgeir@comcast.net
or
Media Relations:
a.s.a.p.r.
Robbie Tarpley Raffish
410-883-2000
NVIC N-Viro International Corporation Announces a Signed Agreement to Dispose Sludge in Israel
N-Viro Designs State-of-the-Art Biosolids Stabilization Plant to be operated in Tel Aviv
Jun 15, 2007 12:12:00 PM
TOLEDO, Ohio, June 15 /PRNewswire-FirstCall/ -- N-Viro International Corp. (OTC Bulletin Board: NVIC.OB) ("N-Viro") announced today it has entered into a contract with an Israeli firm, Dan-Viro, to operate a state-of-the-art N-Viro- designed and patented biosolids stabilization plant ("BSP") at Israel's main wastewater treatment plant in Tel Aviv, Israel. Israeli-based Dan-Viro will initially treat a portion of Tel Aviv's biosolids under a recently signed contract.
Dan-Viro is a consortium made up of Israeli companies with extensive experience in wastewater treatment and agricultural use of soil amendments. Due to their efforts, coupled with N-Viro's proven biosolids treatment process, N-Viro anticipates the BSP will be a permanent component of Tel Aviv's biosolids management program.
"We are extremely pleased to gain this foothold in the Middle East," stated CEO and President Timothy Kasmoch. "The practice of ocean dumping of biosolids must end. N-Viro's patented technology is the perfect solution and our work with Dan-Viro in Israel is an important first step towards a cleaner Mediterranean Sea. We applaud their efforts."
"We are equally excited about the sales potential of N-Viro Soil(TM) in addition to revenue participation, which is generated from the day-to-day operation of the new facility. N-Viro Soil produced at the facility is expected to be marketed and sold in Israel as an agricultural soil amendment," added Mr. Kasmoch.
About NVIC
N-Viro International Corporation develops and licenses its technology to municipalities and private companies. N-Viro's patented processes use lime and/or mineral-rich, combustion byproducts to treat, pasteurize, immobilize and convert wastewater sludge and other bio-organic wastes into biomineral agricultural and soil-enrichment products with real market value. More information about N-Viro International can be obtained by contacting the office or on the Internet at www.nviro.com or by e-mail inquiry to info@nviro.com
Special Cautionary Note Regarding Forward-Looking Statements
The Company cautions that words used in this document such as "expects," "anticipates," "believes" and "may," as well as similar words and expressions used herein, identify and refer to statements describing events that may or may not occur in the future. These forward-looking statements and the matters to which they refer are subject to considerable uncertainty that may cause actual results to be materially different from those described herein. For example, while the Company believes that trends in sludge treatment are moving in favor of the Company's technology, such trends may not continue or may never result in increased sales or profits to the Company because of the availability of competing processes. Additional information about these and other factors that may adversely affect these forward-looking statements are contained in the Company's reports, including its Annual Report on Form 10- KSB, and other filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws.
For More Information Contact:
Timothy Kasmoch, CEO
info@nviro.com (419) 535-6374
SOURCE N-Viro International Corp.
----------------------------------------------
Timothy Kasmoch
CEO of N-Viro International Corp.
+1-419-535-6374
info@nviro.com
ISSI 6.02 Integrated Silicon Solution, Inc. Files Form 10-Qs for December 2006 and March 2007 Quarters
Company Now Current With All Filings With the SEC
Jun 15, 2007 12:06:00 PM
SAN JOSE, Calif., June 15 /PRNewswire-FirstCall/ -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI) filed its Quarterly Reports on Form 10-Q for the quarters ended December 31, 2006 and March 31, 2007 with the Securities and Exchange Commission ("SEC") on June 5, 2007. With these filings, ISSI is now current with all SEC filing requirements. On June 14, 2007, the Nasdaq Listing and Hearing Review Council notified ISSI that it has demonstrated compliance with Nasdaq Marketplace Rules, and will continue to be listed on the Nasdaq Global Market.
About the Company
ISSI is a fabless semiconductor company that designs and markets high performance integrated circuits for the following key markets: (i) digital consumer electronics, (ii) networking, (iii) mobile communications and (iv) automotive electronics. The Company's primary products are high speed and low power SRAM and low and medium density DRAM. The Company also designs and markets EEPROM, SmartCards and is developing selected non-memory products focused on its key markets. ISSI is headquartered in Silicon Valley with worldwide offices in China, Europe, Hong Kong, India, Korea and Taiwan. Visit our web site at http://www.issi.com.
SOURCE Integrated Silicon Solution, Inc.
----------------------------------------------
Scott Howarth
Vice-President & CFO
Investor Relations of Integrated Silicon Solution
Inc.
+1-408-969-6600
ir@issi.com
ABTL 4.30 Language Line Services Names Michael Schmidt as Chief Financial Officer
Jun 15, 2007 12:00:00 PM
Copyright Business Wire 2007
MONTEREY, Calif.--(BUSINESS WIRE)--
Language Line Services today announced the appointment of Michael Schmidt as Senior Vice President of Finance effective July 23, 2007 and Chief Financial Officer and Director effective August 15, 2007. Schmidt will be responsible for supervising financial reporting, tax and legal compliance, administration and capital financing. The announcement was made by CEO Dennis Dracup.
Prior to joining Language Line Services and since 2004, Mr. Schmidt was Senior Vice President of Finance, and was promoted to Chief Financial Officer and Executive Vice President of Autobytel (NASDAQ:ABTL), an automotive marketing and media services company. Before that and since 2002, Mr. Schmidt was Chief Financial Officer and Executive Vice President of Telephia, a market research company focused on the wireless communications industry.
"Michael's background and experience will further strengthen our senior management team and support execution of our growth strategies," said Dennis Dracup, Language Line Services' Chairman and Chief Executive Officer.
Schmidt replaces Jeffrey Grace who is leaving Language Line Services to work as CFO for a privately held company in the Salinas Valley in California. "We appreciate Jeff's efforts on the Company's behalf and wish him the best in his future endeavors," noted Dracup.
The Board of Directors approved the appointment of Solange Jerolimov as interim Chief Financial Officer effective June 15, 2007 until August 15, 2007. Ms. Jerolimov has worked for Language Line Services since 2006 and is currently Controller of the Company.
About Language Line Services
Language Line Services, the world's leading provider of language services, is recognized as a trusted partner to thousands of U.S. based organizations focusing their marketing efforts on the limited English speaking community, which is growing rapidly in both size and affluence. The company provides access to the industry's fastest service at highly competitive rates to all major sectors including government, health care, telecom, financial services and insurance by connecting them to customers, patients and sales prospects in over 170 languages. The growth of the industry has soared with increased immigration and government and regulatory compliance policies mandating organizations provide services to limited English speakers in their own languages. For more information about Language Line, Inc.'s suite of video and over-the phone interpretation services, document translation, and bilingual testing and training please call (800) 752-6096 or visit www.languageline.com.
Source: Language Line Services
----------------------------------------------
Language Line Services
Monterey
Jeanine Faine
305-448-7450
jeanine.faine@rbbpr.com
LOL! ok, gonna paint that price .10!~ lol ;)
LOL>..not really....i am painting and trading...mostly painting :)
PYCT PayChest Announces Further Decreases in Outstanding Share Count
Jun 15, 2007 11:18:00 AM
HUNTINGTON BEACH, CA -- (MARKETWIRE) -- 06/15/07 -- PayChest, Inc. (PINKSHEETS: PYCT) today announced a further decrease in the number of outstanding shares. The reduction of 520 million shares was announced in conjunction with the continued stock audit efforts by the company.
The most recent decrease brings the overall outstanding share count to 16,620,990,045. The stock audit conducted over the past few months has resulted in an overall reduction of 4,425,544,340.
"Our efforts to negotiate a claw back on these shares has been beneficial to the Company overall and continues to establish a firmer stock framework for the company to move forward with its business strategy. We don't expect any further reduction from our audit efforts. The final audit and asset position will be disclosed by the end of next week," said Mr. Pillay, PayChest's CEO.
About PayChest
PayChest and its strategic partner companies have developed an integrated online payment processing platform utilizing cutting edge technologies to deliver payment solutions online. These payment processing solutions include turnkey payment facilitation for credit and debit cards, electronic checks, money transfer solutions, gift cards and turnkey rewards based systems.
New management within PayChest is focused on innovative and tangible products, improving the online financial experience for online consumers and e-commerce businesses worldwide. To fulfill this obligation, the new management has marked significant timelines over the next few months to streamline operations, with a focus on integrating backend transaction processing infrastructures scalable to new payment technologies and marketing opportunities.
Safe Harbor Statement
The foregoing press release contains forward-looking statements. For this purpose any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate," "continue," or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties and actual results may differ materially depending on a variety of factors.
Contact:
PayChest, Inc.
Investor Relations
info@paychest.com
morning! :)
ready to break one way or the other...UP I SAY! lol
mornin! :)
NNSR chart...4x avg vol
XFML 8.64 Xinhua Finance Media Completes Acquisition of M-in
Jun 15, 2007 7:40:00 AM
BEIJING, June 15 /Xinhua-PRNewswire-FirstCall/ -- Xinhua Finance Media ("XFMedia"; Nasdaq: XFML), China's leading diversified financial and entertainment media company, today announced that it has completed its acquisition of a 100% interest in Beijing Mobile Interactive Co., Ltd ("M-in"). The acquisition is intended to enable XFMedia to rapidly integrate mobile service capabilities with its existing range of popular media assets and market a variety of new interactive products and services to more than 487 million mobile phone users in China.
About Xinhua Finance Media Limited
Xinhua Finance Media ("XFMedia"; Nasdaq: XFML) is China's leading diversified financial and entertainment media company targeting high net worth individuals nationwide. The company reaches its target audience via TV, radio, newspapers, magazines and other distribution channels. Through its five synergistic business groups, Advertising, Broadcast, Print, Production and Research, XFMedia offers a total solution empowering clients at every stage of the media process and keeping people connected and entertained.
Headquartered in Beijing, the company has offices and affiliates in major cities of China including Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong. For more information, please visit www.xinhuafinancemedia.com .
Xinhua Finance Media is a subsidiary of Xinhua Finance Limited ("XFL"; TSE Mothers: 9399), China's premier financial information and media service provider. XFL owns 36.9% of the equity and 85.4% of the voting rights of XFMedia through its holding of class B common shares, which have ten votes per share. The investing public, the company's China partners, executives and staff own class A common shares in the company with one vote per share. The dual-class common share structure was created to accommodate the regulatory landscape of China's media sector.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, quotations from management in this announcement contain forward-looking statements. XFMedia may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission on forms 20-F and 6-K, etc., in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about XFMedia's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statements. Potential risks and uncertainties are risks include but are not limited to, the China advertising market may not grow as expected and other risks, outlined in XFMedia's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1. All information provided in this press release is as of the date of this release, and XFMedia undertakes no duty to update such information, except as required under applicable law.
For more information:
China
Xinhua Finance Media
Ms. Joy Tsang,
Tel: +86-21-6113-5999
Email: joy.tsang@xinhuafinancemedia.com
United States
Taylor Rafferty John Dudzinsky
Tel: +1-212-889-4350
Email: john.dudzinsky@taylor-rafferty.com
SOURCE Xinhua Finance Media Limited
----------------------------------------------
Joy Tsang
+86-21-6113-5999
or joy.tsang@xinhuafinance.com of Xinhua Finance; or John Dudzinsky of Taylor Rafferty for XFML
+1-212-889-4350
or john.dudzinsky@taylor-rafferty.com
TEC 5.00 Teton Energy Announces Additions to Natural Gas Hedging Program
Jun 15, 2007 7:30:00 AM
DENVER, June 15 /PRNewswire-FirstCall/ -- Teton Energy Corporation ("Teton") (Amex: TEC) announced today that it will add to its natural gas hedging program starting July 2007 and continuing through October 2008.
Teton entered a Colorado Interstate Gas ("CIG") fixed price swap at a strike price of $5.78 per MMBtu for 30,000 million British Thermal Units ("MMBtu") per month for July 2007 through October 2008, for a total of 480,000 MMBtu for the respective period.
During November 2006, the Company entered into a costless collar hedge for the 2007 calendar year. Teton purchased a CIG put at a price of $6.00 per MMBtu and sold a CIG call at a price of $7.25 per MMBtu each for 30,000 MMBtu per month for January 2007 through December 2007, for a total of 360,000 MMBtu for the 2007 year.
Currently, the Company sells most of its natural gas in the Piceance Basin of Colorado at CIG index prices. The Company completed the hedging transaction with its senior bank, BNP Paribas.
These hedges are intended to improve the Company's financial flexibility by locking in a portion of its revenues and cash flow in the event that natural gas prices decline. The hedging strategy should allow Teton to develop its long-lived producing assets and to increase borrowing under its credit facility with BNP Paribas.
Company Description. Teton Energy Corporation (AMEX: TEC), is an independent oil and gas exploration and production company based in Denver, Colorado. Teton is focused on the acquisition, exploration and development of North American properties and has current operations in the Rocky Mountain region of the U.S. The Company's common stock is listed on the American Stock Exchange under the ticker symbol "TEC". For more information about the Company, please visit the Company's website at http://www.teton-energy.com.
Forward-Looking Statements. This news release may contain certain forward-looking statements, including declarations regarding Teton and its subsidiary's expectations, intentions, strategies and beliefs regarding the future within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements contained herein are based upon information available to Teton's management as at the date hereof and actual results may vary based upon future events, both within and without the control of the Teton's management, including risks and uncertainties that could cause actual results to differ materially including, among other things, the impact that additional acquisitions may have on the company and its capital structure, exploration results, market conditions, oil and gas price volatility, uncertainties inherent in oil and gas production operations and estimating reserves, unexpected future capital expenditures, competition, governmental regulations and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission. More information about potential factors that could affect the Company's operating and financial results are included in Teton's annual report on Form 10-K for the year ended December 31, 2005. Teton's disclosure reports are on file at the Securities and Exchange Commission and can be viewed on Teton's website at http://www.teton-energy.com. Copies are available without charge, upon request from the Company.
SOURCE Teton Energy Corporation
----------------------------------------------
Andrea Brown of Teton Energy Corporation
+1-303-565-4600
abrown@teton-energy.com
CALD 7.99 Silicon Valley / San Jose Business Journal Names Callidus Software Among Top 5 Silicon Valley Companies Reporting Largest Revenue Increase in 2006
Leading Sales Performance Management Provider Also Placed in List of Top 25 Software Developers in Silicon Valley
Jun 15, 2007 7:00:00 AM
SAN JOSE, CA -- (MARKETWIRE) -- 06/15/07 -- Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), today announced that the company has been named one of the top five software companies reporting the largest revenue jump in the fiscal year ended December 31, 2006 by the Silicon Valley / San Jose Business Journal. The publication also included Callidus in its list of Top 25 Software Developers with the biggest revenues.
Callidus Software's industry-leading SPM solutions align sales with corporate objectives to drive revenue and increase shareholder value. Callidus solutions are used by more than 1.5 million salespeople, brokers and channel representatives, and by more Fortune 1000 companies than those from any other sales performance management or incentive compensation management vendor.
Callidus offers on-demand or licensed software, and a strong professional services group with deep vertical market compensation management expertise. Callidus helps its customers to automate and bulletproof global sales program management. The solutions optimize pricing, quota and territory management and facilitate accurate payment of commissions across a global sales force, external partners, distributors and retail outlets.
About Callidus Software®
Callidus Software (www.callidussoftware.com) (NASDAQ: CALD) is a leading provider of on-premise and on-demand Sales Performance Management (SPM) solutions to global companies across multiple industries. Callidus' products allow enterprises to strategically manage incentive compensation, establish quota targets, and align territories, resulting in improved sales and distribution performance. Customers/Partners include 7-Eleven, Accenture, CUNA Mutual, HP, IBM, Philips Medical Systems, Sun Microsystems and Wachovia.
© 2007 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, Callidus TrueAnalytics, TrueChannel, TrueComp, TrueComp Datamart, TrueComp Grid, TrueComp Manager, TrueFoundation, TrueInformation, TrueIntegration, TruePerformance, TrueProducer, TrueQuota, TrueReferral, TrueResolution, TrueService and TrueSupport are trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.
Add to Digg Bookmark with del.icio.us Add to Newsvine